Dashboard
Manage Tickers

PTGX Protagonist Therapeutics, Inc


$ 75.78 $ -1.95 (-2.51 %)    

Thursday, 16-Oct-2025 15:59:59 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 598.23 $ -2.23 (-0.37 %)
DIA $ 458.84 $ -3.15 (-0.68 %)
SPY $ 658.90 $ -4.53 (-0.68 %)
TLT $ 91.49 $ 0.68 (0.75 %)
GLD $ 401.79 $ 9.06 (2.34 %)
$ 75.73
$ 77.81
$ 74.00 x 18
$ 78.49 x 2
$ 74.62 - $ 78.00
$ 33.31 - $ 93.25
1,931,728
na
4.71B
$ 0.93
$ 90.54
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-to-separate-orthopedics-business-boosts-annual-sales-outlook
Johnson & Johnson To Separate Orthopedics ...
10/14/2025 12:51:28

Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthoped...

johnson--johnson-q3-preview-with-stock-near-all-time-highs-heres-what-to-watch
Johnson & Johnson Q3 Preview: With Stock N...
10/13/2025 16:27:44

Johnson & Johnson stock trades near all-time highs with an upcoming Q3 earnings report acting as the next catalyst.

fda-adds-new-warning-for-johnson--johnsons-cancer-cell-therapy
FDA Adds New Warning For Johnson & Johnson...
10/13/2025 14:30:41

FDA updates Johnson & Johnson's Carvykti label to warn of rare immune-related enterocolitis while reaffirming the thera...

Core News & Articles
12 Health Care Stocks Moving In Friday's I...
10/10/2025 17:06:47

johnson--johnson-in-talks-to-acquire-protagonist-therapeutics-report
Johnson & Johnson In Talks To Acquire Prot...
10/10/2025 17:06:05

Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that could expand its immunology and cancer drug po...

protagonist-therapeutics-shares-resume-trade
Protagonist Therapeutics Shares Resume Trade
10/10/2025 15:33:28

protagonist-therapeutics-shares-halted-on-circuit-breaker-to-the-upside-stock-now-up-940
Protagonist Therapeutics Shares Halted On ...
10/10/2025 15:15:37

Core News & Articles
'Johnson & Johnson In Talks To Buy Protago...
10/10/2025 15:15:04

https://www.wsj.com/health/pharma/johnson-johnson-in-talks-to-buy-protagonist-therapeutics-38e0b69d

5-analysts-assess-protagonist-therapeutics-what-you-need-to-know
5 Analysts Assess Protagonist Therapeutics...
10/08/2025 12:01:55

hc-wainwright--co-reiterates-buy-on-protagonist-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Prot...
10/08/2025 10:21:42

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 ...

protagonist-therapeutics-oral-il-23-blocker-icotrokinra-meets-phase-2b-goals-in-ulcerative-colitis-phase-3-trials-set-for-q4-2025
Protagonist Therapeutics' Oral IL-23 Block...
10/07/2025 12:12:09

Icotrokinra met the primary endpoint of clinical response at all three doses, with 36.5% of patients treated achieving endoscop...

demystifying-protagonist-therapeutics-insights-from-4-analyst-reviews
Demystifying Protagonist Therapeutics: Ins...
09/17/2025 20:01:41

johnson--johnson-protagonist-study-shows-superior-skin-clearance-in-psoriasis-trials
Johnson & Johnson, Protagonist Study Shows...
09/17/2025 19:15:33

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

hc-wainwright--co-reiterates-buy-on-protagonist-therapeutics-maintains-80-price-target
HC Wainwright & Co. Reiterates Buy on Prot...
09/17/2025 15:43:39

HC Wainwright & Co. analyst Douglas Tsao reiterates Protagonist Therapeutics (NASDAQ:PTGX) with a Buy and maintains $80 ...

this-protagonist-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-wednesday
This Protagonist Therapeutics Analyst Begi...
09/17/2025 12:15:15

protagonist-presents-new-data-from-phase-3-iconic-advance-1-and-2-studies-which-assessed-icotrokinra-compared-to-deucravacitinib-in-patients-with-moderate-yo-severe-plaque-ppsoriasis
Protagonist Presents New Data From Phase 3...
09/17/2025 12:03:36

barclays-initiates-coverage-on-protagonist-therapeutics-with-overweight-rating-announces-price-target-of-72
Barclays Initiates Coverage On Protagonist...
09/17/2025 10:56:57

Barclays analyst Etzer Darout initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Overweight rating and anno...

protagonist-therapeutics-to-highlight-data-from-phase-2b-anthem-uc-study-with-icotrokinra-in-ulcerative-colitis-at-united-european-gastroenterology-week-2025
Protagonist Therapeutics To Highlight Data...
09/15/2025 14:46:56

Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that data from the Phase 2b ANTHEM-UC...

this-protagonist-therapeutics-analyst-begins-coverage-on-a-bullish-note-here-are-top-3-initiations-for-friday
This Protagonist Therapeutics Analyst Begi...
09/12/2025 12:37:17

leerink-partners-initiates-coverage-on-protagonist-therapeutics-with-outperform-rating-announces-price-target-of-73
Leerink Partners Initiates Coverage On Pro...
09/12/2025 10:56:12

Leerink Partners analyst Faisal Khurshid initiates coverage on Protagonist Therapeutics (NASDAQ:PTGX) with a Outperform rati...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION